About erythropoetin alfa
Erythropoiesis-stimulating agent
Used for
- Treats anemia caused by chronic kidney disease.
- Treats anemia caused by certain chemotherapy regimens.
- Reduces transfusion needs in selected patients having major surgery.
Usual adult dose
Chronic kidney disease: usually 50–100 units/kg intravenously or under the skin three times weekly. Chemotherapy: usually 150 units/kg three times weekly or 40,000 units weekly.
Usual dose in children
Chronic kidney disease: usually 50 units/kg intravenously or under the skin three times weekly; dosing is adjusted by response.
Common side effects
- High blood pressure
- Joint or muscle aches
- Fever or headache
- Blood clots
Important warnings
- Can increase risk of heart attack, stroke, blood clots, and death, especially when hemoglobin targets are high.
- Blood pressure should be controlled and blood counts monitored during treatment.
- Not appropriate for anemia needing immediate correction or for certain cancers without chemotherapy.
- Rarely causes severe allergic reactions or pure red cell aplasia.
Pregnancy
Use only when clearly needed; human pregnancy data are limited. Discuss risks with a healthcare professional.
Breastfeeding
It is unknown whether epoetin alfa passes into human milk; consider treatment needs and infant monitoring.
Interactions
- No major drug interactions are established; blood pressure medicines may need adjustment as blood pressure changes.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.